CJC-1295 without DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been modified to increase stability and bioactivity in preclinical models. Unlike its DAC-bound counterpart, this version has a shorter half-life, allowing for more precise, pulsatile GH release patterns in research settings.